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Abstract 
Aims 
The Warfarin Self-Management Anticoagulation Research Trial (Warfarin SMART) 
was designed to determine whether patients self-managing warfarin (PSM) using the 
CoaguChek device and a dosing algorithm developed for the trial could keep the INR 
(International Normalised Ratio) test in target range at least as often as patients 
managed by usual care by the family doctor or hospital clinic. 
Methods and Results 
310 patients were randomly assigned to PSM or usual care. The PSM group was 
trained to perform home INR testing and warfarin dosing using a validated 
ColourChart algorithm. The primary endpoint was the proportion of times over 12 
months that a monthly, blinded “outcome INR test”, measured in a central laboratory, 
was outside the patients’ target therapeutic range. 
The rate of out-of-range outcome INRs was lower in PSM, and non-inferior to the 
usual care group (PSM: 36% vs. usual care: 41%, P<0.0001 for non-inferiority; 
P=0.08 for superiority in closed-loop testing). The deviations from the patients’ 
midpoint of target INR range (P=0.02) and number of extreme INRs (P=0.03) were 
significantly less in the PSM group than the usual-care group. There was no 
significant difference between groups in rates of bleeding or thrombotic adverse 
events. 
 Conclusion 
Patient self-management performed at least as well as usual care in maintaining the 
INR within the target range, without any safety concerns. This treatment modality for 
the long-term use of warfarin has the potential to change current local and 
international practice. 
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Introduction 
Observational and experimental studies of patients on oral anticoagulation therapy 
show annual fatal bleeding rates of up to 4.8% and major nonfatal bleeding rates of 
2.4% to 8.1%. 1 Although newer oral anticoagulant direct thrombin inhibitor agents 
are available, their high cost and uncertain safety profile will limit their use in the 
short-term. 2, 3  
Careful control of warfarin is critical to prevent bleeding and thromboembolic 
complications. There is evidence that the number of complications increases in 
parallel with the time patients spend outside target therapeutic International 
Normalised Ratio (INR) range. 4, 5 Extreme INRs increase the risk of adverse events. 6 
In one study, the risk of bleeding at an INR over 7 was 40 times the risk at an INR in 
the low therapeutic range (2–2.9) and 20 times the risk at an INR in the high 
therapeutic range (3–4.4). 6 Higher variability of the INR in patients with mechanical 
heart valves is associated with shorter survival. 7 
Patient self-management (PSM) of warfarin may improve anticoagulation control and 
thereby reduce adverse events through convenient, frequent INR testing. The 
CoaguChek coagulometer, a self-testing device, has been shown to be accurate and 
reliable in experimental and clinical studies. 8, 9  
PSM varies in scope from calling an anticoagulation clinic to confirm a dose, to total 
independent management by the patient after one or more teaching sessions. Dosing 
algorithms have occasionally been used in trials of PSM where INR has been 
stabilised already, with good results. 10, 11 Evidence from European trials seems to 
support PSM as a method to improve anticoagulation management outcomes, but 
many randomised studies to date have been biased or small.  
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This large study with an unbiased design with regard to evaluation of outcome INRs 
investigated whether PSM is non-inferior or superior to usual warfarin management. 
PSM using the CoaguChek device and a dosing algorithm was compared to usual care 
by determining the proportion of blinded outcome INRs in the target range. The 
hypothesis test was that the proportion of out-of-range INRs in the PSM group would 
be 6% less than in the usual care group.  
Methods 
Study design 
The study used a randomised controlled trial design to compare 1. standard 
management of warfarin control (usual care) using local laboratory testing and dose 
scheduling by a general practitioner, cardiologist or coagulation clinic with 2. use of 
an INR home self-testing device combined with dosing scheduled via a validated 
home individualised algorithm (PSM). Study staff and trial patients were blinded to 
assessment of the primary outcome. 
Patient population 
Cardiology and cardiac surgery patients from South-Western and Central Sydney 
areas (Liverpool, Royal Prince Alfred, and Strathfield Private Hospitals) in Australia 
were screened and recruited between January 1, 2004 and July 3, 2008 with follow-up 
until July 3, 2009. Patients were receiving warfarin for at least 3 months for either 
atrial fibrillation or for one or more mechanical heart valves. Patients needed to have 
a stable INR within the therapeutic range for the 2 weeks before enrolment, without 
maintenance dose adjustments above 2 mg per day, so that an individual algorithm 
could be developed. Patients were required to be at least 18 years of age, able to be 
contacted by telephone, and assessed by study staff as having adequate English-
language skills, including reading ability. Patients were excluded if they had a known 
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coagulation disorder, underlying liver disease, a condition limiting their ability to 
comply with the study routine such as drug or alcohol addiction, a visual deficit, or 
tremor or tactile dysfunction; or if they failed a mini-mental state evaluation (score <8 
out of 10). They were also excluded if they were unable to comply with monthly 
laboratory INR tests with blood transportable to the central study laboratory. 
All patients gave written informed consent. The study protocol was approved by local 
and national ethics committees and was undertaken in accordance with the 
Declaration of Helsinki and Good Clinical Practice guidelines 
(ACTRN12606000019505). 
Study intervention and randomisation 
All patients received a 60-minute training session in the therapeutic use of warfarin. 
Eligible patients were randomly allocated to ongoing usual care or PSM for 12 
months using a central phone-based randomisation system at the NHMRC Clinical 
Trials Centre. The randomisation method was minimisation, with stratification for age 
(≤65, >65), sex, duration of prior warfarin therapy (3-6 months, >6 months), current 
midpoint of INR range (<2.5, 2.5–2.9, >3.0), indication for warfarin (chronic atrial 
fibrillation, a mechanical heart valve, 2 or more mechanical heart valves) and type of 
management (general practitioner, cardiologist, clinic) before enrolment into the study.  
Study coordinators notified patients of their study group allocation as blinding was 
not possible. Patients allocated to the PSM group received two additional training 
sessions (60 and 45 minutes) on 1. use of the device (CoaguChek S or XS, Roche 
Diagnostics) including internal liquid quality control tests for the CoaguChek S 
device, and 2. use of the self-dosing algorithm (a colour-coded INR warfarin-dosing 
algorithm, Figure 1).  
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The algorithm was validated against records of patients by ensuring dose changes 
using the algorithm were negligible compared to typically prescribed doses.  
The algorithm was unique for each target INR and warfarin dose range and used dose 
adjustments that ranged from 10% to 50% of the maintenance dose (i.e. from 0.5 mg 
for a 5 mg dose to 1 mg for a 2 mg dose) to ensure patients maintained their INR 
range. The time to the next INR measurement was also recommended in the algorithm 
based on INR deviation from the target range. PSM patients checked their INR at 
least once a week, and more frequently if required by the algorithm. Patients were 
instructed to call the study nurse to discuss maintenance dose adjustment if the INR 
was less than 1.6 greater than 4.5, or out-of-range for more than 4 tests. 
The usual-care group was also given instructions on how to complete a black-and-
white chart similar to the ColourChart to record their clinical INR test results but 
without the algorithm instructions: they documented the date of each INR test, the 
result, and the dose they were instructed to take. This process was intended to match 
levels of involvement in individual data tracking in the two groups as far as possible. 
Study outcomes 
For 12 months, all patients had monthly outcome INRs measured at a central 
accredited laboratory (Davies, Campbell, de Lambert, now Symbion Pathology). All 
general practitioners, patients and investigators were blinded to the outcome INR 
results, which were sent to the unblinded statistician at the NHMRC Clinical Trials 
Centre. The only exception to this was that the trial staff were notified when the 
outcome INR readings were in the extreme high range (over 4.5), so that patients and 
their general practitioners could be notified of a potential safety issue (this occurred in 
12/3114 (0.4%) of outcome INR tests ). 
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For each patient, the proportion of out-of-range INRs was calculated and treatment 
groups were compared (primary endpoint). Secondary endpoints included: 1. the 
number of times outcome INR results occurred in extreme ranges (≥4.5, <1.5); and 2. 
rates of serious adverse events related to bleeding or thrombosis.. Subsidiary (tertiary) 
endpoints were: 1. the average deviation from the middle of each individual’s INR 
target range; 2. the mean outcome INR, by treatment group allocation; and 3. time to 
the first INR reading in an extreme range.  
Serious adverse events were classified as embolism, thrombosis, moderate bleeding 
(requiring medical evaluation or treatment, minor and nuisance bleeding excluded), 
severe, life threatening, or fatal bleeding, and other events, and were adjudicated by a 
blinded assessor as to nature and cause (MA). Outcome INR results and serious 
adverse events were monitored by an Independent Safety and Data Monitoring 
Committee (ISDMC). 
Statistical analysis 
The study was designed to detect a 10% difference between assigned groups in the 
proportion of INR readings outside the therapeutic range. A sample size of 310 
patients was expected to offer at least 80% power, with a two-sided alpha, with 95% 
confidence, to detect such a difference, allowing for up to 10% drop-ins to PSM in 
some form, and up to 10% dropouts from PSM. The investigators considered it 
reasonable to miss a 20% effect because of the number of smaller studies and the high 
number of patients that would have been required to obtain 90% power. During the 
study, the blinded Steering Committee determined that a non-inferior outcome for 
PSM would be meaningful owing to the convenience afforded by home testing, 
provided that the PSM strategy proved safe. Consequently, the planned study analysis 
was modified to a closed testing procedure, first of non-inferiority with a pre specified 
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margin of 6% in rate of out-of-range values followed by superiority testing if non-
inferiority was satisfied. The margin of 6% was empirically based on the maximum 
plausible risk of detriment that would not outweigh the added convenience of home 
testing and dosing with PSM. 
The primary test for comparison was the two-sample t test. The primary endpoint data 
was normally distributed along with the other continuous endpoints and thus 
parametric tests could be used.  
A secondary analysis used generalised estimating equations, with a compound 
symmetric correlation structure and a logistic link, to account for the repeated 
measures for each patient. Statistical inferences were drawn for a two-sided P value of 
less than 5%. All analyses were unadjusted and based on the intention-to-treat 
principle.  
Results 
Screening and baseline characteristics 
Of 1722 subjects screened for the trial, 310 were eligible and consented to be 
randomised (Figure 2). The treatment groups were generally well-balanced with 
respect to baseline and anticoagulation characteristics, including the span of the 
prescribed INR range (Table 1). Compliance with trial participation was generally 
good, with only 11 (7%) subjects allocated to PSM withdrawing during the treatment 
period and 24 (15%) allocated to usual care withdrawing from monthly provision of 
central-outcome blood samples at some time during the 12-month follow-up period. 
Patients who withdrew from the PSM group were managed by their usual practitioner. 
One subject was lost to follow-up (usual care group). The mean number of outcome 
INRs captured was 10.1 out of a possible 12. All patients were analysed for the 
primary outcome. 
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The mean number of blinded outcome INRs obtained, the mean value of the blinded 
outcome INRs, and the mean warfarin dose taken did not appear to differ between 
groups (Table 2). The primary endpoint, the proportion of out-of-range INRs, was 
non-significantly lower for the PSM-allocated group (40.7% usual care versus 35.5% 
PSM), just failing to reach significance for superiority (P=0.08), but being highly 
significant for non-inferiority, with the one-sided 95% confidence interval being 
much greater than –6% (at +5.2%, P<0.001).  
Self-managed patients also had significantly fewer extreme INR readings (P=0.03) 
and a smaller average deviation over all readings from the centre of their individual 
target INR ranges than the usual-care patients (difference = 0.04; 95% CI, 0.01–0.09, 
P=0.02). No significant differences were seen between treatment groups for the 
proportion of subjects with at least one reading in an extreme range at any time. There 
is evidence that the time to the first extreme reading was 46% longer among those 
allocated to the PSM group (95% CI, 20%–103%, P=0.05; Figure 3). 
There was no difference in the rate of serious adverse events (Table 3). Irrespective of 
treatment allocation, there were more than twice as many bleeding as thrombotic 
events. The only death, of a patient with pulmonary hypertension and severe cardiac 
dysfunction who died from recurrent intracerebral haemorrhage, was arbitrated by the 
ISDMC to be due to warfarin therapy (but not in the extreme range) and not related to 
the study protocol. 
Discussion 
Summary of findings 
Frequent INR testing combined with a warfarin management algorithm for self-
management is as good as usual care, and superior to usual care in some aspects of 
warfarin control. The primary study analysis, comparing proportion of out-of-range 
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INR readings, showed non-inferiority of PSM. PSM was also associated with 
significantly less variability of readings and fewer extreme readings (≥4.5 or <1.5), 
both of which are of major clinical importance in relation to risk of bleeding or 
thrombotic complications. 
Potential mechanisms for PSM benefit 
PSM may offer better control by more frequent testing, allowing earlier adjustment of 
warfarin dose when the INR deviates from the therapeutic range. In usual care, 
general practitioners may increase the time interval between INR checks for the 
patient’s convenience. Educating patients about the dosing algorithm, and daily use of 
the algorithm, may improve motivation and compliance with testing and dose 
adjustment, improving the quality of anticoagulation control in PSM. 
Possible study limitations explained 
The eligibility criteria were designed to be minimally restrictive. There was no 
requirement as to education level or age. No patient was excluded based on the mini-
mental exam. Almost 40% of patients were aged over 65 years, and 25% were over 70 
years, indicating a balance of young and old patients who were able to use the test 
device and dosing self-management algorithm.  
A single laboratory network was used to ensure consistency of quality control 
procedures for outcome INR measurement. Of the 1722 screened patients, 356 
(20.7%) were ineligible because they lived too far from a pathology laboratory 
thereby limiting the trial to patients in the city areas. In real practice rural patients 
could self-manage warfarin. Self management would facilitate in-range INRs 
compared to usual care in rural areas because testing and general practitioner 
management (usual care) are likely to be less accessible in rural than urban areas.  
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Inability to understand English (10.3%) was an exclusion criteria but this group of 
patients could have been included in real practice provided an English-speaking 
family member was available for education.  
Of all patients screened for the study, 27.4% declined to participate, largely because 
of a preference for usual care and the difficulty in attending the single laboratory for 
outcome INRs. Only a small proportion of screened patients were ineligible based on 
inclusion and exclusion criteria (21.8%). The two major reasons for withdrawal were 
difficulty in attending for the outcome INR test (9 of 35 withdrawals; 25.7%) and a 
request by the patient to withdraw (8 of 35 withdrawals; 22.9%). 
There was potential risk of bias because of inability to blind the investigators or 
patients to the treatment. The patients in the PSM treatment group may have felt 
privileged and more motivated than the usual care group to maintain the INR in the 
target range. If present, it is likely that this effect is small because of GP control of 
dosing in the patient population. Patient education about the warfarin dosing 
algorithm may have improved the outcome in the PSM group. However, the usual-
care group also learned and used a black-and-white chart similar to the ColourChart 
which may have improved their performance slightly.  
Greater INR variability may result from usual care patients managed mostly by 
general practitioners rather than anticoagulation clinic specialists.12 Here, INR results 
were determined by a central laboratory blinded to treatment, which eliminated bias in 
terms of the outcome INR. 
 INR measurement device and primary endpoint 
In a study comparing the CoaguChek S and XS with plasma INR testing, the device 
had good correlation with lab measurement (r2 of 0.9). 13 Correlation decreased at 
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high INR levels and laboratory testing was recommended. All INR methods (lab and 
point of care testing), however, may provide variable INR results for the same 
sample.14 The CoaguChek S and XS differ in the way the instrument measures the 
prothrombin time. The CoaguChek S uses a photometric principle where the 
CoaguChek XS uses an electrochemical detection system. The XS replaced the S in 
January 2007 after a voluntary recall of the S test strips by Roche Diagnostics. This 
was to avoid a <0.001% chance of a potential test strip defect that may cause falsely 
elevated test results.  
Measurement bias of any INR method is dependent on the way each particular 
method is standardised and traceable to higher-level standards. For the CoaguChek, 
each lot of test strips is calibrated to a reference lot that is traceable to the WHO 
International Reference Preparations. The International Sensitivity Index (ISI) for the 
system has been confirmed as 1.0. 
Time in therapeutic range (TTR) can be determined in different ways, so comparisons 
between studies may be difficult. TTR is commonly estimated by using proportion of 
out-of-range INRs. Since clinical outcome studies have not compared one 
methodology with another and correlated their results with adverse events, no one 
method can be recommended over the other.15, 16 The proportion of out of range INRs 
reported in other studies is 21% to 51%, the results of this study being consistent with 
those studies.17–21 
Significance and strengths of this study 
This study is of interest in Asian-Pacific and North American regions where self 
testing and self management are not as widespread as in Europe. Valve companies 
issue self measurement devices to patients who have had mechanical valve 
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replacement. Patients self test INR and possibly even self manage, as is widely done 
in Germany. 
This study is the largest randomised trial with an unbiased design of outcome 
measurement demonstrating PSM to be as good as usual care in terms of 
anticoagulation control and the proportion of INRs in the target range. It was designed 
to avoid the inherent bias in evaluating differing numbers of INR tests between 
groups. In many studies, the PSM group have undergone more frequent testing than 
those receiving usual care. The proportion of INR readings falling out of range may 
then be a lower percentage of the total number of tests, even when the instances of 
out-of-range episodes are identical (Figure 4).  
The other strengths of this study are the medium-term follow-up of one year and the 
intention-to-treat method of analysis. Furthermore, assessment of potentially 
haemorrhagic and thromboembolic events was restricted to blinded assessors. The 
high capture rate of serious adverse events in both groups may have been due to use 
of the Australian Medicare (Health Insurance Commission) database and diagnosis 
related group (DRG) designation from admitting hospitals rather than reliance on 
reporting by patients.  
Consistency with other studies 
Of the 11 randomised trials included in the recent Cochrane review of warfarin self-
management, only three used central blinded outcome INR tests, and all were smaller 
than our study. 17 Two (n=50, n=100) were unable to show a difference in outcome 
INR measurements with PSM. 18, 19 The third, a well-designed, unbiased but smaller 
trial (n=179), showed a higher proportion of INRs in target range for PSM than usual 
care. 22 The present, larger study adds weight to that study by proving non-inferiority 
of PSM.  
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Limitations of other large studies on out-of-range INRs 
The Early Self-Controlled Anticoagulation Trial (ESCAT) series of studies on PSM, 
were large and showed that PSM was associated with a greater time within the 
therapeutic INR range, and a decreased rate of thromboembolism and bleeding events 
23. However, these studies have been criticised 12 because there was more frequent 
testing in the PSM group, and follow-up studies included additional patients and a 
different primary endpoint (long-term survival) 24.  
A large, randomised trial of PSM, by Menéndez-Jándula et al.23, showed improved 
time in range but was limited by testing up to 6 times as frequently in the PSM group. 
Another large (n=617) randomised controlled trial was unable to show a difference in 
time in range between PSM and conventional management. 24  
Two large meta-analyses of time in therapeutic INR range favoured PSM or patient 
self-testing, but again did not analyse equivalent numbers of INR measurements in 
each group, thereby potentially introducing bias.12, 25 
Significance of randomised trials and meta-analyses with serious adverse events 
as an outcome measure 
Because of the paucity of high-quality, randomised trials, PSM has not been shown to 
reduce serious adverse events other than in a selected population of elderly patients. 26 
This positive result may have been due to the high rate of haemorrhage in those over 
70 years of age. 27  
Another recent randomised study of PST 28 was unable to show a difference in clinical 
outcomes despite a large number of patients (n=2922). Perhaps, addition of PSM may 
have improved the clinical outcomes in that trial.  
A large meta-analysis of individual patient data (6417 patients) from randomised 
trials included a heterogeneous group of trials of PST only and trials of PSM. 29 A 
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pre-specified subgroup analysis showed a reduction in events in the PSM group but 
the self-testing individuals were not significantly different from the control group. 
This adds evidence to the positive impact of PSM on adverse events. 
A meta-analysis of 22 randomised trials with PST or PSM, 5 of which were 
considered high quality, showed an improvement in thromboembolic complications 
and death. 30 In another meta-analysis of 10 randomised trials of PSM, there was a 
reduction in death and major complications when PSM was used. 25 Only 2 of the 
trials were considered to be high quality and the positive effect of PSM on risk of 
death was not evident in these two trials. The effect of PSM, therefore, needs to be 
clearly delineated from PST alone when designing meta-analyses and randomised 
trials about the clinical outcomes of warfarin therapy. 
Conclusions 
The Warfarin SMART study, the largest of its kind with an unbiased design of 
outcome INR measurement, was powered to determine whether home PSM offers 
comparable or better INR and warfarin management than usual care. PSM performed 
at least as well as usual care in maintaining INR within target range, with significantly 
fewer extreme readings and smaller INR variability. This was achieved safely and has 
the potential to change current practice. This study supports the positive, smaller, well 
designed randomised trial by Sawiki12, several meta-analyses with surrogate markers 
for adverse events, and meta-analyses showing reduction in adverse events with PSM. 
A large, definitive randomised trial of PSM is required to determine the effect on 
clinical outcomes. 
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Legends 
Figure 1 
Sample algorithm for a patient using the ColourChart 
Figure 2 
Flow chart for SMART study 
Figure 3 
Proportion of patients over time with at least one INR reading in an extreme range 
(high ≥4.5; low <1.5). Log-rank P=0.05. 
Figure 4 
More frequent testing of the INR can lead to higher proportion of tests being out of 
range despite the same number of INR spikes out of range. 
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Table 1: Baseline characteristics 
 
Usual care 
(n=157) 
Self-management 
(n=153) 
Male 111 (71%) 103 (67%) 
Age at randomisation (years) 60.1 (11.5) 59.3 (13.1) 
Age >65 years 58 (37%) 59 (39%) 
Height (cm) 173.8 (10.6) 172.6 (9.6) 
Weight (kg) 83.4 (19.6) 80.3 (18.3) 
Caucasian 147 (94%) 138 (90%) 
Education at secondary level or 
higher 
156 (99%) 149 (97%) 
English primary language 145 (92%) 141 (92%) 
Full-time or part-time 
employment 
75 (48%) 74 (48%) 
Current or exsmoker 73 (46%) 69 (45%) 
Consumes alcohol 128 (82%) 122 (80%) 
NYHA class II or higher 18 (11%) 18 (12%) 
Diabetes 19 (12%) 36 (24%) 
Hypertension 75 (48%) 71 (46%) 
Previous cerebral vascular 
accident 
17 (11%) 10 (7%) 
Previous transient ischaemic 
attack 
9 (6%) 16 (10%) 
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Usual care 
(n=157) 
Self-management 
(n=153) 
Warfarin for valve(s) ± atrial 
fibrillation 
111 (71%) 110 (72%) 
Chronic atrial fibrillation 64 (41%) 66 (43%) 
Mechanical heart valves   
 0 46 (29%) 44 (29%) 
 1  101 (64%) 99 (65%) 
 2+ 10 (6%) 10 (7%) 
Years since surgery 4.0 (5.8) 3.4 (4.3) 
Prestudy management   
 By general practitioner 152 (97%) 147 (96%) 
 By laboratory or clinic 4 (3%) 6 (4%) 
 By cardiologist 1 (1%) 0 (0%) 
Prior time on warfarin >6 
months 
116 (74%) 110 (72%) 
Midpoint of target INR range   
 < 2.5 4 (3%) 3 (2%) 
 2.5– 2.9 56 (36%) 48 (31%) 
 ≥3.0 97 (62%) 102 (67%) 
Width of target INR range 0.9 (0.2) 0.9 (0.2) 
INR range   
 Upper limit 3.3 (0.3) 3.3 (0.3) 
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Usual care 
(n=157) 
Self-management 
(n=153) 
 Midpoint  2.87 (0.27) 2.85 (0.29) 
 Lower limit 2.4 (0.3) 2.4 (0.3) 
All statistics are means (SD) or n (%) 
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Table 2: Main results 
Outcomes 
Usual care 
(n=157) 
Self-
management 
(n=153) P 
Treatment    
INRs per patient, mean (SD) 9.7 (3.0) 10.4 (2.2) —* 
Warfarin dose (mg), mean (SD) 5.2 (2.1) 5.8 (2.4) —* 
Primary endpoint 
INRs out of target range,% (SD) 40.7% (24.0%) 35.5% (26.0%) 
Noninferiority 
<0.001 
Superiority 
0.08 
Secondary endpoint† 
Total INR readings in extreme range  
(≥4.5 or <1.5), n (%)** 
20 (1.4%) 10 (0.6%) 0.03 
Other endpoints 
Deviation from target midrange (IU), mean (SD) 0.48 (0.17) 0.44 (0.18) 0.02 
Mean outcome INR (IU), mean (SD) 2.6 (0.4) 2.6 (0.3) —* 
At least one INR in extreme range, % 11.8% 6.7% 0.132 
INRs above target INR range (%), mean (SD) 7.5% (11.8%) 7.4% (12.3%) 0.92 
INRs below target INR range (%), mean (SD) 33.2% (25.8%) 28.2% (25.6%) 0.10 
* Not calculated. 
† Adverse events was another secondary endpoint (table 3) 
** As a percent of all blinded outcome INR readings
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Table 3: Serious adverse events  
 Usual care Self-management 
Event Events Patients Events Patients 
Bleeding 17 16 15 15* 
Embolism or thrombosis 7 7 3 3 
* 1 patient with recurrent intracranial haemorrhages and chronic heart failure died of multi-organ 
failure after surgery.  
 
 
 
 
